Quick Answer
UroGen Pharma Ltd. reported Cash And Cash Equivalents At Carrying Value of $110.75 million for the year ending 2025.
- UroGen Pharma Ltd. showed a decrease of -35.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), UroGen Pharma Ltd.'s Cash And Cash Equivalents At Carrying Value has grown by 2,761.6%.
- Historical annual values: Fiscal year 2025: $110.75 million | Fiscal year 2024: $171.99 million | Fiscal year 2023: $95.00 million | Fiscal year 2022: $55.41 million | Fiscal year 2021: $44.36 million | Fiscal year 2020: $52.86 million | Fiscal year 2019: $49.69 million | Fiscal year 2018: $101.32 million | Fiscal year 2017: $37.00 million | Fiscal year 2016: $21.36 million | Fiscal year 2015: $17.98 million | Fiscal year 2014: $3.87 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: